Rhythm Pharmaceuticals Appoints Kim Popovits to Board, Ed Mathers Departs
Rhythm Pharmaceuticals named Kim Popovits to its Board of Directors and accepted the departure of longtime director Ed Mathers. Popovits brings over 40 years of biotech leadership, including overseeing Oncotype DX commercialization at Genomic Health, to bolster governance and commercialization as the company advances its obesity treatment IMCIVREE.
1. Board Restructuring
Rhythm Pharmaceuticals updated its Board of Directors by appointing Kim Popovits and accepting the resignation of Ed Mathers. The changes reflect a strategic shift to strengthen oversight and expand commercial expertise as the company progresses its lead obesity therapy.
2. Background on Kim Popovits
Kim Popovits joins with over 40 years of experience in biotechnology and diagnostics. She previously led Genomic Health as CEO, driving the development and global rollout of the Oncotype DX genomic test, and held senior commercial roles at Genentech.
3. Departure of Ed Mathers
Ed Mathers, a board member since 2013, steps down after more than a decade of service. During his tenure, Mathers provided strategic guidance on clinical development and corporate governance that supported Rhythm’s transition to a commercial-stage company.
4. Strategic Implications
The board adjustments aim to enhance commercial leadership and governance as Rhythm focuses on expanding patient access to IMCIVREE and progressing its clinical pipeline. Popovits’s track record in reimbursement strategy could accelerate market penetration for the company’s rare disease therapies.